Alzheimer's disease and gut microbiota: does trimethylamine N-oxide (TMAO) play a role?

Nutr Rev. 2022 Jan 10;80(2):271-281. doi: 10.1093/nutrit/nuab022.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that affects memory and cognitive function. Clinical evidence has put into question our current understanding of AD development, propelling researchers to look into further avenues. Gut microbiota has emerged as a potential player in AD pathophysiology. Lifestyle factors, such as diet, can have negative effects on the gut microbiota and thus host health. A Western-type diet has been highlighted as a risk factor for both gut microbiota alteration as well as AD development. The gut-derived trimethylamine N-oxide (TMAO) has been previously implied in the development of cardiovascular diseases with recent evidence suggesting a plausible role of TMAO in AD development. Therefore, the main goal of the present review is to provide the reader with potential mechanisms of action through which consumption of a Western-type diet could increase AD risk, by acting through microbiota-produced TMAO. Although a link between TMAO and AD is far from definitive, this review will serve as a call for research into this new area of research.

Keywords: Alzheimer’s disease; gut–brain axis; insulin resistance; microbiota; trimethylamine n-oxide.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / etiology
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Methylamines
  • Neurodegenerative Diseases*

Substances

  • Methylamines
  • trimethyloxamine